Autologous dendritic cell immunotherapy - APAC Biotech

Drug Profile

Autologous dendritic cell immunotherapy - APAC Biotech


Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APAC Biotech
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Clinical Phase Unknown Glioblastoma; Renal cell carcinoma

Most Recent Events

  • 13 Apr 2017 Clinical trials in Renal cell carcinoma and Glioblastoma in India (IV) (APAC Biotech's website, April 2017)
  • 05 Apr 2017 Phase-II clinical trials in Solid tumours (Second-line therapy or greater) in India (IV)
  • 05 Apr 2017 Preregistration for Prostate cancer, Ovarian, Colo-rectal and Non Small Cell Lung carcinoma (Second-line therapy or greater) in India (IV) before April 20174
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top